Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.
December 04, 2023 | 2:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating on Unicycive Therapeutics and maintained a $3 price target.
The reiteration of a Speculative Buy rating and the maintenance of a $3 price target by a Benchmark analyst could lead to increased investor confidence and potential upward movement in UNCY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100